Vident Advisory’s Ionis Pharmaceuticals IONS Stock Holding History

Vident Advisory’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$808K	Buy	10,187 +698	+7%	+$52.5K	0.01%	1097
2026 Q1	$713K	Sell	9,489 -746	-7%	-$58.9K	0.01%	1052
2025 Q4	$810K	Sell	10,235 -1,316	-11%	-$99.1K	0.01%	911
2025 Q3	$756K	Sell	11,551 -449	-4%	-$21.9K	0.01%	968
2025 Q2	$474K	Buy	+12,000	New	+$393K	0.01%	1084
2024 Q2	–	Sell	-4,796	Closed	-$208K	–	1462
2024 Q1	$208K	Sell	4,796 -134	-3%	-$6.39K	﹤0.01%	1197
2023 Q4	$249K	Sell	4,930 -656	-12%	-$31.4K	0.01%	1105
2023 Q3	$253K	Buy	+5,586	New	+$230K	0.01%	1003

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vident Advisory's IONS Position: Q2 2026 in Review

Vident Advisory increased its Ionis Pharmaceuticals (IONS) stake by 7.4% in Q2 2026, buying an estimated $52.5K and bringing the position to 10,187 shares worth $808K. The position accounts for 0.01% of the portfolio, ranked #1097.

Vident Advisory first reported a position in IONS in Q3 2023 and has held it in 8 quarters since. The position peaked at $810K in Q4 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Vident Advisory held 10,187 shares of Ionis Pharmaceuticals worth $808K as of Q2 2026.
Vident Advisory bought 698 Ionis Pharmaceuticals shares in Q2 2026, an estimated $52.5K.
Ionis Pharmaceuticals made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #1097 holding.
Vident Advisory first reported a position in Ionis Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
Vident Advisory's Ionis Pharmaceuticals position peaked at $810K in Q4 2025.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.